News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
415 Results
Type
Article (25)
Company Profile (1)
Press Release (389)
Section
Business (81)
Deals (17)
Drug Development (131)
FDA (10)
Job Trends (5)
News (237)
Policy (27)
Tag
Accelerated approval (1)
Alliances (19)
Alzheimer's disease (13)
Approvals (10)
Autoimmune disease (1)
Best Places to Work (1)
Biotechnology (1)
Cardiovascular disease (8)
Cell therapy (3)
Clinical research (104)
Collaboration (2)
C-suite (2)
Data (4)
Earnings (33)
Events (53)
Executive appointments (3)
FDA (13)
Friedreich's ataxia (1)
Funding (2)
Gene editing (1)
Gene therapy (9)
GLP-1 (1)
Healthcare (1)
Immunology and inflammation (1)
IPO (10)
Job creations (2)
Layoffs (2)
Legal (1)
Manufacturing (1)
Mergers & acquisitions (7)
Metabolic disorders (1)
Neurodegenerative disease (1)
Neuroscience (14)
NextGen: Class of 2026 (6)
Obesity (1)
Opinion (1)
People (31)
Phase 1 (18)
Phase 2 (60)
Phase 3 (38)
Pipeline (7)
Postmarket research (3)
Preclinical (12)
Rare diseases (4)
Regulatory (30)
Schizophrenia (1)
Series B (1)
Special edition (1)
Spinal muscular atrophy (1)
Startups (5)
Vaccines (3)
Venture capital (1)
Date
Last 7 days (1)
Last 30 days (4)
Last 365 days (37)
2026 (6)
2025 (33)
2024 (33)
2023 (24)
2022 (19)
2021 (18)
2020 (9)
2019 (7)
2018 (7)
2017 (22)
2016 (18)
2015 (24)
2014 (24)
2013 (38)
2012 (35)
2011 (31)
2010 (27)
Location
Asia (12)
Australia (3)
California (6)
Canada (1)
China (1)
Europe (25)
Florida (1)
Massachusetts (5)
Nevada (1)
New York (34)
Northern California (2)
Pennsylvania (1)
South America (1)
Southern California (4)
United States (45)
415 Results for "lexeo therapeutics.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in February 2026
February 5, 2026
·
1 min read
Press Releases
Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy
January 8, 2026
·
4 min read
Press Releases
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics
January 28, 2026
·
7 min read
Press Releases
Lexeo Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 23, 2025
·
1 min read
Press Releases
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy
January 12, 2026
·
7 min read
Layoffs
Lexeo Trims 15% of Workforce, Shifts Focus to Lead Cardiac Programs
Lexeo wants to more quickly move investigational gene therapy LX2006 into a registrational study and hopes for a potential efficacy readout in 2027.
May 12, 2025
·
1 min read
·
Angela Gabriel
Press Releases
Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights
November 6, 2025
·
10 min read
Press Releases
Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement
October 17, 2025
·
5 min read
Press Releases
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum
December 4, 2025
·
1 min read
Gene therapy
Lexeo Plots Pivotal Path for Friedreich’s Ataxia Gene Therapy After ‘Compelling’ Phase I/II Data
Stifel analysts said that Lexeo’s data showing reduced size and thickness of the heart’s left ventricle are “supportive of a drug effect” for the company’s gene therapy in Friedreich’s ataxia cardiomyopathy.
April 8, 2025
·
2 min read
·
Tristan Manalac
1 of 42
Next
